Eli Lilly and Company NYQ · LLY
Price alert —
Sign in to get a one-time email the moment LLY crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · LLY
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $19.8B | $7.4B | $9.8B | $2.8B | 37.4% | 49.4% |
| 2025-12-31 | $19.3B | $6.6B | $9.0B | $0.3B | 34.4% | 46.6% |
| 2025-09-30 | $17.6B | $5.6B | $8.4B | $6.0B | 31.7% | 47.6% |
| 2025-06-30 | $15.6B | $5.7B | $7.0B | $1.3B | 36.4% | 45.1% |
| 2025-03-31 | $12.7B | $2.8B | $5.3B | $-1.6B | 21.7% | 41.7% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare LLY vs peers
Line LLY up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with LLY
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-30 | 8.55 | 6.79 | +25.9% | +3.1% |
| 2026-02-04 | 7.54 | 6.91 | +9.1% | -7.8% |
| 2025-10-30 | 7.02 | 5.89 | +19.1% | +2.2% |
| 2025-08-07 | 6.31 | 5.59 | +12.9% | -2.4% |
| 2025-05-01 | 3.34 | 3.46 | -3.4% | +3.7% |
| 2025-02-06 | 5.32 | 5.07 | +5.0% | +0.9% |
| 2024-10-30 | 1.18 | 1.47 | -19.5% | -2.0% |
| 2024-08-08 | 3.92 | 2.77 | +41.7% | +5.5% |
| 2024-04-30 | 2.58 | 2.49 | +3.7% | -0.6% |
| 2024-02-06 | 2.49 | 2.37 | +5.1% | +2.9% |
| 2023-11-02 | 0.10 | -0.12 | +181.5% | -2.1% |
| 2023-08-08 | 2.11 | 1.99 | +5.9% | +0.9% |
| 2023-04-27 | 1.62 | 1.73 | -6.3% | +1.4% |
| 2023-02-02 | 2.09 | 1.83 | +14.1% | +2.5% |
| 2022-11-01 | 1.98 | 1.94 | +2.1% | +0.7% |
| 2022-08-04 | 1.25 | 1.70 | -26.3% | -1.5% |
| 2022-04-28 | 2.62 | 2.29 | +14.4% | -1.7% |
| 2022-02-03 | 2.49 | 2.51 | -0.7% | -1.0% |
| 2021-10-26 | 1.94 | 1.96 | -1.2% | +0.7% |
| 2021-08-03 | 1.87 | 1.89 | -1.0% | +2.5% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LLY ★ | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
| ABT | $175B | 28.2 | 16.6 | 3.8 | 17.1 | 3.4 | 56.8% | 13.0% | -47.5% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 43.16%
| Holder | Shares | % out |
|---|---|---|
| Lilly Endowment, Inc | 91,896,978 | 9.76% |
| Blackrock Inc. | 66,380,842 | 7.05% |
| Vanguard Capital Management LLC | 53,361,774 | 5.67% |
| PNC Financial Services Group, Inc. | 51,328,908 | 5.45% |
| State Street Corporation | 35,610,002 | 3.78% |
| FMR, LLC | 26,341,031 | 2.80% |
| Capital Research Global Investors | 24,632,647 | 2.62% |
| Vanguard Portfolio Management LLC | 20,977,027 | 2.23% |
| Geode Capital Management, LLC | 20,191,864 | 2.14% |
| Capital World Investors | 15,621,813 | 1.66% |
Insider activity · 90d
12 buys / 3 sells · ratio 4.0 · Finnhub
- LUCIANO JUAN R BUY 16,891 @ $1129.35
- Fyrwald J Erik BUY 75,401 @ $1129.35
- Alvarez Ralph BUY 55,723 @ $1129.35
- Sulzberger Gabrielle BUY 2,995 @ $1129.35
- Yuffa Ilya SELL 29,804 @ $1150.77
- LUCIANO JUAN R BUY 16,851 @ $988.09
- Fyrwald J Erik BUY 75,280 @ $988.09
- Alvarez Ralph BUY 55,627 @ $988.09
- Sulzberger Gabrielle BUY 2,987 @ $988.09
- LILLY ENDOWMENT INC SELL 91,881,150 @ $996.18
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-11 | FORM 4 | view · |
| 8-K | 2026-05-20 | 8-K | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| 4 | 2026-05-07 | Insider transaction (Form 4) | view · |
| 10-Q | 2026-04-30 | 10-Q | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 4 | 2026-04-21 | FORM 4 | view · |
| 4 | 2026-04-21 | FORM 4 | view · |
| 4 | 2026-04-21 | FORM 4 | view · |
| 4 | 2026-04-21 | FORM 4 | view · |
| DEF 14A | 2026-03-20 | DEF 14A | view · |
| 4 | 2026-03-17 | FORM 4 | view · |
| 4 | 2026-03-17 | FORM 4 | view · |
| 4 | 2026-03-17 | FORM 4 | view · |
| 4 | 2026-03-17 | FORM 4 | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 10-K | 2026-02-12 | 10-K | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 8-K | 2026-02-04 | 8-K | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-01-21 | FORM 4 | view · |
| 4 | 2026-01-21 | FORM 4 | view · |
| 4 | 2026-01-21 | FORM 4 | view · |
| 4 | 2026-01-21 | FORM 4 | view · |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for …
Options picks · LLY
ITM + OTM ideas from the latest scanLoading…
Congress trades · LLY
STOCK Act disclosuresLoading…
SEC filings & insiders · LLY
EDGAR · liveLoading…
Holders · LLY
Institutions & insider activityLoading…